EUCTR2008-007969-23-GB进行中（未招募）1 期
A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCER
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,059
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Screening and recruitment was completed under protocol amendment 2
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 317
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 742
排除标准
- •Screening and recruitment was completed under protocol amendment 2
研究者
相似试验
进行中（未招募）
1 期
The evaluation of lenalidomide, with or without Docetaxel plus Prednisone, in the treatment of prostate cancer, when the cancer does not respond to hormonal treatmentChemo-naïve metastatic prostate cancer subjects with documented rising Prostate Specific Antigen (PSA) or documented Progressive Disease (PD) following hormonal therapyMedDRA version: 18.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-007969-23-DECelgene Corporation1,059
进行中（未招募）
1 期
A STUDY TO EVALUATE DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCERChemo-naïve metastatic prostate cancer subjects with documented rising Prostate Specific Antigen (PSA) or documented Progressive Disease (PD) following hormonal therapyMedDRA version: 13.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-007969-23-GRCelgene Corporation1,015
进行中（未招募）
1 期
The evaluation of lenalidomide, with or without Docetaxel plusPrednisone, in the treatment of prostate cancer, when the cancer does not respond to hormonal treatmentChemo-naïve metastatic prostate cancer subjects with documented rising Prostate Specific Antigen (PSA) or documented Progressive Disease (PD) following hormonal therapyMedDRA version: 15.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-007969-23-SECelgene Corporation1,059
进行中（未招募）
不适用
The evaluation of lenalidomide, with or without Docetaxel plusPrednisone, in the treatment of prostate cancer, when the cancer does not respond to hormonal treatmentChemo-naïve metastatic prostate cancer subjects with documented rising Prostate Specific Antigen (PSA) or documented Progressive Disease (PD) following hormonal therapyMedDRA version: 14.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-007969-23-CZCelgene Corporation1,059
进行中（未招募）
1 期
The evaluation of lenalidomide, with or without Docetaxel plusPrednisone, in the treatment of prostate cancer, when the cancer does not respond to hormonal treatmentChemo-naïve metastatic prostate cancer subjects with documented rising Prostate Specific Antigen (PSA) or documented Progressive Disease (PD) following hormonal therapyMedDRA version: 19.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-007969-23-DKCelgene Corporation1,059